Browse by category

REMAIN-1: Durable weight maintenance one year after GLP-1 discontinuation

Fractyl Health has announced positive one-year results from its REMAIN-1 Midpoint Cohort, reinforcing the potential of the Revita DMR System (Revita) to be the first durable procedural therapy for post-GLP-1 weight maintenance. The key findings include: Dose-dependent durability confirmed at one year: In the full modified intention-to-treat (mITT) population (N=45), a single Revita procedure reduced weight regain by approximately 40% versus sham at one year (least-squares mea

Fractyl Health provides update on clinical studies priorities

Fractyl Health is prioritising its REMAIN-1 pivotal study, addressing the demand for an off-ramp to GLP-1 drugs, while advancing its...

FDA Approves IDE study assessing Revita for weight maintenance after discontinuation of GLP-1

The FDA has approved a pivotal Investigational Device Exemption (IDE) to study the efficacy of Fractyl Health’s Revita system for...

Framework focuses on the effects of excess adiposity on organs and tissues

Jul 31

First US patient treated with Proximal Intestinal Mucosal Ablation for the treatment of T2DM

Jul 28

Medtronic unveils Touch Surgery Aide - the next-generation compute platform for the OR

Jul 23